描述 |
Puromycin dihydrochloride是嘌呤霉素的二盐酸盐。 Puromycin是一种抑制 protein synthesis 的氨基糖苷类抗生素。 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
相关类别 |
|
||||||||||||
体外研究 |
嘌呤霉素在氨酰基-sRNA形成后阻断蛋白质合成,同时它导致小肽的积累。这两种效应似乎都是由于核糖体结合的肽基-sRNA的分裂,导致不完整肽链的释放[1]。嘌呤霉素是氨酰基-tRNA的3′末端的类似物,通过与生长的多肽链非特异性连接而导致翻译过早终止。嘌呤霉素具有两种抑制作用模式。第一种是通过作为受体底物,其攻击P位点中的肽基-tRNA以形成新生肽。第二种是通过与氨酰基-tRNA竞争结合A’位点[2]。当以最小量使用时,嘌呤霉素掺入新合成的蛋白质直接反映体外mRNA翻译的速率。嘌呤霉素免疫检测是放射性氨基酸标记的有利替代方案。它允许通过免疫荧光显微镜直接评估单细胞中的翻译活性,并通过荧光激活细胞分选直接评估异质细胞群[3]。 |
||||||||||||
溶解度 |
体外:
DMSO:≥77.5mg / mL(142.35 mM) H 2 O:50 mg / mL(91.84 mM;需要超声波和加温) * “≥”表示可溶,但饱和度未知。 体内:1。逐个添加每种溶剂:10%DMSO 90%(20%SBE-β-CD在盐水中)溶解度:≥2.58mg/ mL(4.74mM);澄清溶液2.逐个添加每种溶剂:10%DMSO 40%PEG300 5%吐温-80 45%盐水溶解度:≥2.58mg/ mL(4.74mM);澄清溶液3.逐个添加每种溶剂:10%DMSO 90%玉米油溶解度:≥2.58mg / mL(4.74 mM);明确解决方案
|
||||||||||||
储备液 |
|
||||||||||||
存储 |
|
||||||||||||
运输 |
室温;可能会有所不同 |
||||||||||||
SMILES |
OC[C@@H]1[C@@H](NC([C@@H](N)CC2=CC=C(OC)C=C2)=O)[C@H]([C@H](N3C=NC4=C3N=CN=C4N(C)C)O1)O.[H]Cl.[H]Cl |
||||||||||||
参考文献 |
|
||||||||||||
相关活性 小分子 |
G-418 硫酸盐 | 衣霉素 | 潮霉素B | 盐霉素 | 阿维巴坦钠 | 硫酸新霉素 | 法硼巴坦 | 甲氧西林钠 | 利福平 | 甲硝唑 | 羧苄青霉素钠 | 头孢他啶 | Eravacycline dihydrochloride | 头孢噻肟钠 | 氯霉素 |
密度 | 1.5±0.1 g/cm3 |
---|---|
熔点 | 168-170℃ |
分子式 | C22H31Cl2N7O5 |
分子量 | 544.43 |
PSA | 160.88000 |
LogP | 0.93 |
外观性状 | 白色粉末 |
折射率 | 1.701 |
储存条件 |
本品应充氩气密封于0℃以下干燥避光保存。 |
稳定性 | Stable. Heat sensitive. Incompatible with strong oxidizing agents. |
水溶解性 | H2O: soluble50mg/mL (Sterilize stock solution by filtration using 0.22 μm filter then store in aliquots at 20 °C.) | Soluble in water |
分子结构 |
五、分子性质数据: 1、 摩尔折射率:120.56 |
更多 |
1. 性状:结晶。有吸湿性。对光敏感。 2. 密度(g/mL,25/4℃): 未确定 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(?C):175.5~177.0 5. 沸点(?C,常压):未确定 6. 沸点(?C):140-150℃(1.33×10-5kPa) 7. 折射率:未确定 8. 闪点(?C):未确定 9. 比旋光度(?):-11 10. 自燃点或引燃温度(?C):未确定 11. 蒸气压(kPa,25?C):未确定 12. 饱和蒸气压(kPa,60?C):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(?C):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值:未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性:易溶于水。 |
|
嘌呤霉素盐酸盐毒性英文版
|
符号 |
GHS07 |
---|---|
信号词 |
Warning |
危害声明 |
H302 |
个人防护装备 |
Eyeshields;Faceshields;Gloves;half-mask respirator (US);multi-purpose combination respirator cartridge (US) |
危害码 (欧洲) |
Xn |
风险声明 (欧洲) |
R22 |
安全声明 (欧洲) |
S36 |
危险品运输编码 | UN 3249 |
WGK德国 | 3 |
RTECS号 | AU7355000 |
包装等级 | III |
危险类别 | 6.1(b) |
由白色链球菌(Streptomyces.alboniger)发酵制得。
Autophagy is involved in the initiation and progression of Graves’ orbitopathy. Thyroid 25(4) , 445-54, (2015)
Differentiation of orbital fibroblasts into mature adipocytes and subsequent accumulation of adipose tissue has been shown in the progression of Graves’ orbitopathy (GO). Autophagy is involved in adip…
|
|
Mining the human autoantibody repertoire: isolation of potent IL17A-neutralizing monoclonal antibodies from a patient with thymoma. MAbs 6(6) , 1608-20, (2014)
Anti-cytokine autoantibodies have been widely reported to be present in human plasma, both in healthy subjects and in patients with underlying autoimmune conditions, such as autoimmune polyendocrinopa…
|
|
DEF6, a novel substrate for the Tec kinase ITK, contains a glutamine-rich aggregation-prone region and forms cytoplasmic granules that co-localize with P-bodies. J. Biol. Chem. 287(37) , 31073-84, (2012)
Localization of DEF6 (SLAT/IBP), a Rho-family guanine nucleotide exchange factor, to the center of the immune synapse is dependent upon ITK, a Tec-family kinase that regulates the spatiotemporal organ…
|
|
PUROMYCIN |
EINECS 200-387-8 |
MFCD00067313 |
L-3′-(a-Amino-p-methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine Dihydrochloride |
PUROMYCIN HYDROCHLORIDE |
Puromycin dihydrochloride |
Purine, 6-dimethylamino-9-[3-(p-methoxy-L-phenylalanylamino)-3-deoxy-.β.-D-ribofuranosyl]-, dihydrochloride |
L-3′-(a-Amino-p-methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine |
(S)-3′-[[2-Amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3′-deoxy-N,N-dimethyladenosine |
puromycinum [INN_la] |
6-Dimethylamino-9-[3-deoxy-3-(p-methoxy-L-phenylalanylamino)-b-D-ribofuranosyl]-b-purine |
Adenosine, 3′-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3′-deoxy-N,N-dimethyl-, hydrochloride (1:2) |
P 638 dihydrochloride |
3′-{(E)-[(2S)-2-Amino-1-hydroxy-3-(4-methoxyphenyl)propylidene]amino}-3′-deoxy-N,N-dimethyladenosine |
3123-L |
3′-Deoxy-N,N-dimethyl-3′-[(O-methyl-L-tyrosyl)amino]adenosine dihydrochloride |
3′-(a-Amino-p-methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine |
3′-(a-Amino-p-methoxyhydrocinnamamido)-3′-deoxy-N,N-dimethyladenosine Dihydrochloride |
Stylomycin dihydrochloride |
6-Dimethylamino-9-[3-deoxy-3-(p-methoxy-L-phenylalanylamino)-b-D-ribofuranosyl]-b-purine Dihydrochloride |
Stillomycin |
Adenosine, 3′-[[(1E,2S)-2-amino-1-hydroxy-3-(4-methoxyphenyl)propylidene]amino]-3′-deoxy-N,N-dimethyl- |
Adenosine, 3′-[[(2S)-2-amino-3-(4-methoxyphenyl)-1-oxopropyl]amino]-3′-deoxy-N,N-dimethyl- |
3′-Deoxy-N,N-dimethyl-3′-[(O-methyl-L-tyrosyl)amino]adenosine |